Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Shares Gap Up After Analyst Upgrade

Bayer Aktiengesellschaft (OTCMKTS:BAYRY)’s stock price gapped up before the market opened on Tuesday after JPMorgan Chase & Co. upgraded the stock from a neutral rating to an overweight rating. The stock had previously closed at $10.10, but opened at $10.40. Bayer Aktiengesellschaft shares last traded at $10.4810, with a volume of 130,543 shares traded.

Several other research analysts have also commented on the company. Zacks Research lowered Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. Morgan Stanley raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, December 3rd. Finally, Wall Street Zen raised Bayer Aktiengesellschaft from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy”.

Bayer Aktiengesellschaft Stock Up 2.0%

The firm has a market capitalization of $42.01 billion, a price-to-earnings ratio of -118.76, a PEG ratio of 5.31 and a beta of 0.69. The business’s fifty day moving average price is $8.34 and its 200 day moving average price is $8.05. The company has a current ratio of 1.13, a quick ratio of 0.73 and a debt-to-equity ratio of 1.04.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.